Abstract:The detection of bisphosphonates is important due to the potential integrity and welfare issues associated with use of these substances. Targeted detection of a nitrogenous and non‐nitrogenous bisphosphonate was detected for 8 h and 28 days post‐administration, respectively. With this, the need for complementary indirect detection using lipid and corticosteroid biomarkers was investigated. Putative biomarkers were identified, which are now subject to validation into routine analysis for improved detection capabilities of bisphosphonate misuse in equine plasma. Detecting the use of bisphosphonates (BPs) in equine athletes is of interest to regulators and laboratories due to the threat to welfare issues for the potential to provide analgesic effects and manipulating bone structure. The detection of BPs in biological matrices is challenging due to erratic biological elimination and inconsistent analytical recoveries. Therefore, complementary approaches are needed to provide evidence of their misuse in racehorses. BPs have two sub‐classes: nitrogenous and non‐nitrogenous. This study investigated plasma elimination following administration of one example from each sub‐class, together with changes in endogenous eicosanoid and corticosteroids. Zoledronic acid (ZA) and tiludronic acid (TA) were administered by IV infusion to 8 thoroughbred horses with an 11‐month washout period between each administration. Sample preparation for quantification of BPs by liquid chromatography–tandem mass spectrometry (LC–MS/MS) utilised a two‐step solid phase extraction (SPE) consisting of polymeric reversed‐phase followed by weak anion exchange prior to derivatisation using trimethyl orthoacetate. Endogenous biomarkers were analysed after protein precipitation and SPE with polymeric reversed‐phase prior to liquid chromatography–high resolution mass spectrometry (LC‐HRMS) using data independent acquisition. The LC–MS/MS analysis showed ZA was undetectable after 8 h post‐administration while TA was detected up to the final collection point of 28 days post‐administration. The LC‐HRMS analysis utilised targeted (i.e., prior inclusion list of compounds) approaches to monitor level changes of eicosanoid and corticosteroid biomarkers. Putative biomarkers were identified and now subject to validation for translation into routine sample analysis for improved retrospectivity to detecting BP misuse in equine plasma.

Equine Doping Controls of Thymosin β $$ \beta $$ 4: A Population Study and Strategy for Misuse Detection

Equine Doping Controls of Thymosin β 4: A Population Study and Strategy for Misuse Detection

3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma

Doping control analysis of myo‐inositol trispyrophosphate and 10 bisphosphonates in equine plasma by ion chromatography–mass spectrometry and its application to clodronic acid horse administration

A Broad-Spectrum Peptide Screening Method Using an Optimized Solid-Phase Extraction and Liquid Chromatography–High-Field Asymmetric Ion Mobility Spectrometry–Mass Spectrometry for Doping Control in Equine Urine

Bayesian Individual Limits for IGF-1 Monitoring in Equine Plasma: Implementation in the Equine Biological Passport

Non-Targeted Detection of Synthetic Oligonucleotides in Equine Serum Using Liquid Chromatography–High-Resolution Mass Spectrometry

Gene Doping Control Analysis of Human Erythropoietin Transgene in Equine Plasma by PCR-Liquid Chromatography High-Resolution Tandem Mass Spectrometry

Discovery of Biomarkers of a Recombinant Human Erythropoietin Administration to Thoroughbred Geldings by Label-Free Proteomics

PCR-Based Equine Gene Doping Test for the Australian Horseracing Industry

Identification and differentiation of somapacitan, a long-acting growth hormone derivative, and recombinant human growth hormone in equine plasma by LC-HRMS for doping control purpose

Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration

Gene doping control analysis of human erythropoietin transgene in equine plasma by PCR-liquid chromatography high resolution tandem mass spectrometry

Analytical advances in horseracing medication and doping control from 2018 to 2023

Transcriptomic Markers of Recombinant Human Erythropoietin Micro-Dosing in Thoroughbred Horses

Lipid and Corticosteroid Biomarkers Under the Influence of Bisphosphonates

Enhanced analysis of equine plasma for the presence of recombinant human erythropoietin - Implementation of an improved workflow

Detection of transgenes in equine dried blood spots using digital PCR and qPCR for gene doping control

High-Throughput Equine Doping Controls on a Trapped Ion Mobility Quadrupole-Time-of-Flight Mass Spectrometer: Technical Considerations of dia/slice/prmPASEF Applied to the Long-Term Detection of Monoclonal Antibodies

Investigation Into the Equine Metabolism of Phosphodiesterase‐4 Inhibitor Roflumilast for Potential Doping Control

A method for detecting gene doping in horse sports without DNA extraction